Yuanshi Tech Funding
5 steps1 pieces4 Sources
Shanghai-based AI biotech startup Yuanshi Technology (also referred to as MetaIntelli Tech in some English reports) has completed a Pre-A funding round of nearly 300 million RMB, led by Legend Capital. This transaction sets a new record for single-round financing in China's AI Virtual Cell (AIVC) sector. The company, founded in April 2026, focuses on building general-purpose cell models that predict cellular responses to diseases and interventions through a "dry-wet closed loop" of model prediction, experimental validation, and data feedback. The funds will be allocated to automated experimental platform construction, data accumulation, and team expansion. Key investors include Huaxia Lingtou, China Merchants China Direct Investments, JD-affiliated funds, CDH VGC, and CMC Capital, with existing shareholders like Monolith and Sinovation Ventures increasing their stakes. The leadership team features CEO Wu Jiaqi, a Peking University PhD with Rockefeller University postdoc experience, and CTO Dong Mingze, a Yale PhD and former Anthropic researcher who joined full-time in November 2026. Investors highlight the strategic shift from molecular design to system-level biological prediction, viewing virtual cells as the next frontier for AI in drug discovery.
How it got here
April 2026: Yuanshi Technology is founded in Shanghai, focusing on AI virtual cell models.
zhidx.com ↗October 22, 2026: The company announces the completion of its Angel and Angel+ rounds, raising close to 100 million RMB combined, led by Sinovation Ventures, Shanghai Engine Fund, Yanyuan Fund, and Monolith Management.
vcbeathealth.com ↗November 6, 2026: Yuanshi Technology signs a strategic cooperation agreement with MGI Tech subsidiary Yongsheng Intelligent during the CIIE to co-build an automated virtual cell experimental platform.